UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~March 269, 2026

Aclaris Therapeutics, Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-37581	46-0571712
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

701 Lee Road, Suite 103

Wayne, PA 19087

(Address of principal executive offices, including zip code)

(484) 324-7933

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class:		Trading Symbol(s)		Name of Each Exchange on which Registered
Common Stock, $0.00001 par value		ACRS		The Nasdaq Stock Market, LLC



Title of Each Class:	Trading Symbol(s)	Name of Each Exchange on which Registered
Common Stock, $0.00001 par value	ACRS	The Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 27.0201 ~~Results~~Regulation ofFD ~~Operations and Financial Condition~~Disclosure.

From March 2, 2026 through March 9, 2026, Aclaris Therapeutics, Inc. (the “Company”) sold 12.7 million shares of its common stock, for aggregate gross proceeds of $39.8 million pursuant to the Company’s amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. (the “Agents”) dated February 27, 2025. The Agents have informed the Company that the shares were purchased by institutional investors including Deep Track Capital.

OnIn ~~February~~accordance ~~26,~~with ~~2026,~~General ~~Aclaris~~Instruction ~~Therapeutics~~B.2. of Form 8-K, ~~Inc~~the information in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “~~Registrant~~Exchange Act”), ~~issued~~or aotherwise ~~press~~subject ~~release~~to ~~announcing~~the ~~its~~liability ~~financial~~of ~~results for~~that section, nor shall it be deemed incorporated by reference in any of the ~~quarter~~Company’s ~~and~~filings ~~full~~under ~~year~~the Securities ~~ended~~Act ~~December~~of 311933, ~~2025.~~as amended, or under the AExchange ~~copy~~Act, whether made before or after the date hereof, regardless of ~~this~~any ~~press~~incorporation ~~release~~language isin ~~furnished~~such ~~herewith~~a filing, except as ~~Exhibit~~expressly ~~99.1~~set toforth ~~this~~by ~~Current~~specific ~~Report~~reference in such a filing.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~Item 9.01 Financial Statements and Exhibits.~~

		ACLARIS THERAPEUTICS, INC.

	By:	/s/ Kevin Balthaser
Date: March 9, 2026		Kevin Balthaser
		Chief Financial Officer

~~(d) Exhibits~~


Exhibit
Number		Exhibit Description
99.1		Press Release, dated February 26, 2026.
104		The cover page from Aclaris Therapeutics, Inc.’s Form 8-K filed on February 26, 2026, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


		ACLARIS THERAPEUTICS, INC.

Date: February 26, 2026	By:	/s/ Kevin Balthaser
		Kevin BalthaserChief Financial Officer

Filing Compare · Aclaris Therapeutics, Inc.